RxDoctor Payments Data

Ayodele Ogunfowora, MD

Psychiatry · Columbia, SCNPI 1073578506

Payments from drug & device makers

$2,655in general payments, 2019–2025

Across 140 payments — averaging $18.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$579
  • Neurocrine Biosciences, Inc.$458
  • Alkermes, Inc.$361
  • Supernus Pharmaceuticals, Inc.$276
  • Teva Pharmaceuticals USA, Inc.$172
  • Otsuka America Pharmaceutical, Inc.$160
  • plus $649 from 9 others

What the payments were for

  • Food & beverage$2,60898%
  • Education$472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,655 in reported general payments places this provider in the 80th percentile of 624 psychiatry providers in South Carolina.

See all psychiatry providers in South Carolina

Medicare billing

Part B allowed, 2024
$23,713
Medicare patients
106
Services billed
307

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate36$129,306
Abilify MaintenaAripiprazole20$58,627
VraylarCariprazine Hcl27$38,714
FanaptIloperidone11$17,598
RexultiBrexpiprazole11$15,929
Aripiprazole200$11,568
Risperidone OdtRisperidone15$7,230
Divalproex Sodium ErDivalproex Sodium88$4,668
Olanzapine100$4,527
Risperidone281$3,178
Paliperidone ErPaliperidone19$2,367
Benztropine Mesylate197$2,225
Ziprasidone Hcl18$2,092
Divalproex Sodium74$2,009
Trazodone Hcl350$1,877

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$579$129,30636 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$160$74,55531 claims
AbbVieVraylar$150$38,71427 claims
Vanda Pharmaceuticals Inc.Fanapt$36$17,59811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 624 psychiatry providers in South Carolina.

Other psychiatry in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →